144. レノックス・ガストー症候群 Lennox-Gastaut syndrome Clinical trials / Disease details

臨床試験数 : 111 / 薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61

15 trials found

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05485831 (ClinicalTrials.gov)	April 2023	29/7/2022	Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY	Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD100 mg/ml) Oral Solution ...	Lennox Gastaut Syndrome;Dravet Syndrome	Drug: Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Evidilya S.r.l.	Not yet recruiting	6 Years	17 Years	All	70		Italy
2	NCT04611438 (ClinicalTrials.gov)	March 30, 2020	16/9/2019	Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Sy ...	A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on ...	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: Cannabidiol	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	107	Phase 3	Korea, Republic of
3	NCT02815540 (ClinicalTrials.gov)	February 16, 2017	20/6/2016	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Sever ...	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children	Lennox-Gastaut Syndrome;Dravet Syndrome	Procedure: 12-Lead ECG;Drug: Cannabidiol	Gillette Children's Specialty Healthcare	NULL	Terminated	2 Years	30 Years	All	2	Phase 1/Phase 2	United States
4	EUCTR2014-002941-23-NL (EUCTR)	30/09/2015	31/03/2015	Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatmen ...	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of canna ...	Lennox-Gastaut syndrome MedDRA version: 19.0;Level: PT;Classification code 10048816;Term: Lennox-Gas ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	100		United States;Poland;Netherlands
5	EUCTR2014-001834-27-NL (EUCTR)	09/09/2015	18/06/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or ...	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
6	EUCTR2014-001834-27-FR (EUCTR)	03/09/2015	20/07/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or ...	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	530	Phase 3	United States;France;Spain;Poland;Israel;Netherlands;United Kingdom
7	EUCTR2014-001834-27-PL (EUCTR)	18/08/2015	14/05/2015	An open label study of the safety of cannabidiol (GWP42003-P) in children and adults with Dravet or ...	An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
8	EUCTR2014-002940-42-GB (EUCTR)	28/07/2015	26/09/2014	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatm ...	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of canna ...	Lennox-Gastaut syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification code 10048816;Term: Lenn ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 3	France;United States;Spain;United Kingdom
9	EUCTR2014-002941-23-PL (EUCTR)	16/07/2015	01/04/2015	Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatmen ...	A randomized, double-blind, placebo-controlled study toinvestigate the efficacy and safety of cannab ...	Lennox-Gastaut syndrome MedDRA version: 18.1;Level: PT;Classification code 10048816;Term: Lennox-Gas ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Poland;Netherlands
10	NCT02224560 (ClinicalTrials.gov)	June 8, 2015	21/8/2014	Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children a ...	A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Canna ...	Epilepsy;Lennox Gastaut Syndrome	Drug: GWP42003-P;Drug: Placebo control	Jazz Pharmaceuticals	NULL	Completed	2 Years	55 Years	All	225	Phase 3	United States;France;Spain;United Kingdom

First Previous1 2Next Last